Department of Cardiac Surgery, Binzhou Medical University Hospital, 661 Huanghe 2nd Road, Binzhou 256603, China.
Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Faculty of Life Sciences, Northwest University, 229 Taibai North Road, Xi'an 710069, China.
Oxid Med Cell Longev. 2021 Mar 9;2021:8873581. doi: 10.1155/2021/8873581. eCollection 2021.
Recent studies have recognized several risk factors for cardiopulmonary bypass- (CPB-) associated acute kidney injury (AKI). However, the lack of early biomarkers for AKI prevents practitioners from intervening in a timely manner. We reviewed the literature with the aim of improving our understanding of the risk factors for CPB-associated AKI, which may increase our ability to prevent or improve this condition. Some novel early biomarkers for AKI have been introduced. In particular, a combinational use of these biomarkers would be helpful to improve clinical outcomes. Furthermore, we discuss several interventions that are aimed at managing CPB-associated AKI, may increase the effect of renal replacement therapy (RRT), and may contribute to preventing CPB-associated AKI. Collectively, the conclusions of this paper are limited by the availability of clinical trial evidence and conflicting definitions of AKI. A guideline is urgently needed for CPB-associated AKI.
最近的研究已经认识到了几种与体外循环(CPB)相关的急性肾损伤(AKI)的风险因素。然而,缺乏 AKI 的早期生物标志物使得临床医生无法及时进行干预。我们回顾了相关文献,旨在加深对 CPB 相关 AKI 风险因素的理解,这可能提高我们预防或改善这种情况的能力。一些新的 AKI 早期生物标志物已经被引入。特别是,这些生物标志物的联合使用将有助于改善临床结局。此外,我们还讨论了几种旨在管理 CPB 相关 AKI 的干预措施,这些措施可能会增加肾脏替代治疗(RRT)的效果,并有助于预防 CPB 相关 AKI。总的来说,本文的结论受到临床试验证据的限制和 AKI 定义的冲突。CPB 相关 AKI 急需一个指南。